[Therapy of orthostatic disorders of cardiovascular regulation. Placebo controlled double-blind study with oxilofrine].
In a double-blind study, the antihypotensive agent oxilofrine was compared with placebo in patients suffering from orthostatic circulatory regulation disorders of the sympathicotonic type. After a washout period of one week, 30 patients were treated for two weeks with oxilofrine and 30 with placebo. The area of the blood pressure amplitude determined with the Schellong test between the 8th minute prone and the 15th minute erect, increased during treatment with oxilofrine from 126 +/- 21 mmHg x min. to 187 +/- 39 mmHg x min. (increase: 48%). The increase under placebo was only 20.8%. The difference in the primary variable was significant. The systolic pressure at the end of treatment with oxilofrine in the Schellong test was virtually constant; under placebo, the systolic pressure decreased.
Pohl
K
K
Rehabilitationsklinik Höchenschwand, Albert-Roussel-Pharma GmbH, Wiesbaden.
Kriech
W
W
D000328:Adult; D001794:Blood Pressure / Q000187:drug effects; D004311:Double-Blind Method; D004809:Ephedrine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D007024:Hypotension, Orthostatic / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D013566:Sympathomimetics / Q000627:therapeutic use*
D013566:Sympathomimetics; C026055:oxilofrine; D004809:Ephedrine
Therapie orthostatischer Kreislaufregulationsstörungen. Plazebo-kontrollierte Doppelblindstudie mit Oxilofrin.